Here is the patent application following your outline:

---

# DESCRIPTION  

## BACKGROUND  

The field of immunotherapy has long struggled with inconsistent correlations between observed immune status changes in patients and clinical outcomes. Traditional approaches to characterizing immunity, such as describing regulatory T cells (Tregs) as a percentage of CD4+ cells or lymphocytes, fail to account for critical factors like lymphopenia or the dynamic interactions between different leukocyte populations. Immunity fundamentally depends on the likelihood of leukocyte interactions within a given volume of blood, making the absolute frequency of each immune cell type essential for predicting immune responses.  

Current systems-based approaches to human immunity include gene expression arrays, cytokine profiling, immunohistochemistry, and multiparameter flow cytometry. However, these methods often rely on relative measurements or require processing steps that may alter the immune cell composition. There remains an unmet need for a comprehensive, quantitative method to characterize immune phenotypes in a manner that captures the systemic relationships between immune cells and their clinical implications.  

## SUMMARY  

The present invention provides a novel methodology for comprehensively characterizing human immunity by quantifying immune cell populations in whole blood and applying hierarchical clustering to identify distinct immune profiles. The method involves flow cytometric analysis of peripheral blood to determine the absolute cell counts per microliter (cells/μl) of defined immune markers, including granulocytes, lymphocytes, monocytes, T cells, B cells, natural killer (NK) cells, regulatory T cells (Tregs), and immunosuppressive monocytes (e.g., CD14+HLA-DRlo/neg).  

By normalizing individual immune marker values to healthy volunteer baselines and applying unsupervised hierarchical clustering, the invention identifies common immune phenotypes, termed "immune profiles," within and across disease states. These profiles reveal shared immunological characteristics that correlate with clinical outcomes, independent of the underlying disease. For example, patients with immune profiles resembling those of healthy volunteers exhibit significantly longer survival compared to those with aberrant profiles.  

Additionally, the method uncovers novel relationships between immune cell populations, such as the inverse correlation between CD4+ T cells and immunosuppressive CD14+HLA-DRlo/neg monocytes. This discovery led to the development of a prognostic biomarker—the ratio of CD4+ cells to CD14+HLA-DRlo/neg monocytes—which stratifies patients into high- and low-risk groups.  

## DETAILED DESCRIPTION  

The invention encompasses a systematic approach to immune profiling, comprising the following steps:  

1. **Sample Collection and Preparation**: Peripheral blood is collected from patients and healthy volunteers under standardized conditions. Whole blood is used to minimize processing artifacts, and absolute cell counts are determined using calibrated flow cytometry techniques, such as BD TruCount™ tubes.  

2. **Flow Cytometric Analysis**: Immune markers are stained directly in whole blood using fluorochrome-conjugated antibodies targeting lineage-specific surface markers (e.g., CD3, CD19, CD56, CD4, CD25, CD14, HLA-DR). Red blood cells are lysed, and leukocytes are fixed for analysis. Cell populations are quantified as cells/μl, enabling direct comparison across samples.  

3. **Data Normalization and Clustering**: Immune marker values are normalized to the mean values of healthy volunteers. The normalized data is log-transformed and subjected to unsupervised hierarchical clustering (e.g., Euclidean average linkage) to group individuals with similar immune phenotypes. Principal component analysis (PCA) further validates profile distinctions.  

4. **Immune Profile Identification**: Clusters with ≥7 members are designated as immune profiles. Profiles are characterized by unique patterns of immune cell frequencies, such as elevated granulocytes and immunosuppressive monocytes in one profile versus lymphopenia in another.  

5. **Clinical Correlation**: Profiles are linked to clinical outcomes (e.g., survival) using statistical models (e.g., Cox regression, Kaplan-Meier analysis). For example, patients in profiles resembling healthy immunity exhibit prolonged survival, while those in aberrant profiles have poorer prognoses.  

6. **Biomarker Development**: Key immune relationships identified through clustering (e.g., CD4+ T cells vs. CD14+HLA-DRlo/neg monocytes) are translated into prognostic ratios or scores.  

### EXAMPLES  

**Example 1: Immune Profiling in Glioblastoma (GBM)**  
Peripheral blood from 27 GBM patients and 40 healthy volunteers was analyzed. Hierarchical clustering revealed three immune profiles:  
- **Profile 1**: 32 healthy volunteers and 5 untreated GBM patients.  
- **Profile 2**: 8 healthy volunteers and 4 untreated GBM patients.  
- **Profile 3**: 13 dexamethasone-treated GBM patients (p < 0.0001).  
Profile 3 was associated with immunosuppression and poorer outcomes, demonstrating the method’s ability to stratify patients by immune status.  

**Example 2: Cross-Disease Immune Profiles**  
Analysis of 200+ subjects (GBM, NHL, RCC, ALI, and healthy volunteers) identified five major immune profiles. Principal component analysis confirmed distinct clustering (Figure 2B). Patients in Profiles 1 and 2 (healthy-like) had a median survival of 915 days vs. 379 days for Profiles 3–5 (p = 0.009), highlighting the prognostic utility of immune profiling.  

**Example 3: CD4+/CD14+HLA-DRlo/neg Ratio as a Biomarker**  
The inverse relationship between CD4+ T cells and CD14+HLA-DRlo/neg monocytes was leveraged to create a prognostic ratio. Patients with a ratio >2.0 had a median survival of 30 months vs. 9 months for those with a ratio ≤2.0 (p = 0.006).  

**Advantages of the Invention**:  
- Eliminates biases from relative immune cell reporting.  
- Identifies shared immune dysregulation across diseases.  
- Enables precision immunotherapy by matching patients to immune profiles.  
- Discovers novel immune cell relationships (e.g., MDSCs independent of granulocytes).  

--- 

This application provides a standalone, comprehensive description of the invention using formal patent language and adhering to the specified outline. Let me know if you'd like any refinements.